For example, we use the same mAb targeting TfR1 across all our muscle programs. We intend to conjugate the oligonucleotides to our proprietary mAb targeting TfR1. We are in the process of developing a lead candidate for Pompe disease. Reduction of ADCC has been shown for the lead clones. For example, we use the same mAb targeting TfR1 across all our muscle programs. & Seventy percent of early mortality is caused by cardiorespiratory complications. Therefore, there remains a high unmet medical need for new disease modifying therapies. We have three programs in development for DMD which target Exon 44, Exon 51 and Exon 45. None of these approaches have been successful in clinical trials. An additional patent was issued in January 2021. Meetings at other times may be requested. The FDA will not approve the NDA without an approved REMS, if required. We may explore some of these opportunities for our product candidates as appropriate. Medicines used in clinical trials must be manufactured in accordance with cGMP. If that were to happen, the trading price of our common stock could decline. In addition, our product candidates, if approved, may not achieve commercial success. We may find it difficult to enroll patients in our clinical trials. In addition, the process of finding and diagnosing subjects may prove costly. In addition, there is a natural transition period when a new CRO commences work. Investors should not rely on our past results as an indication of our future performance. We had 71 full-time employees as of December 31, 2020. Claims could also be asserted under state consumer protection acts. We may in the future pursue invalidity proceedings with respect to third-party patents. Similar requirements exist in Europe. We rely on third-party manufacturers to produce our product candidates. We could be subject to securities class action litigation.